CUPERTINO, Calif., May 18, 2022
/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced
that Dr. James E. Brown, President
and CEO, Dr. Norman Sussman, Chief
Medical Officer, and Dr. WeiQi Lin,
Executive Vice President of R&D, will be participating in a
fireside chat hosted by Ed Arce,
Managing Director of Equity Research at H.C. Wainwright.
Presentation details are as follows:
H.C. Wainwright Global Investment Conference
Date:
|
May 24, 2022
|
Time:
|
On-demand, starting at
7:00 am Eastern Time
|
Format:
|
Fireside chat hosted by
Ed Arce
|
Webcast:
|
https://journey.ct.events/view/4a81754f-ac5c-45a4-a514-0fc8a77705ab
|
The webcast link of the presentation will also be available by
accessing DURECT's homepage at www.durect.com and clicking on
"Event Calendar" under the "Investors" section.
Management will also be available for virtual 1x1 meetings from
May 23-25, 2022 during the
conference. If attendees would like to request a meeting,
please contact H.C. Wainwright directly.
About DURECT Corporation
DURECT is a biopharmaceutical company committed to
transforming the treatment of acute organ injury and chronic liver
diseases by advancing novel and potentially lifesaving therapies
based on its endogenous epigenetic regulator program. Larsucosterol
(also known as DUR-928), DURECT's lead drug candidate, binds to and
inhibits the activity of DNA methyltransferases (DNMTs), epigenetic
enzymes which are elevated and associated with hypermethylation
found in alcohol-associated hepatitis (AH) patients. Larsucosterol
is in clinical development for the potential treatment of AH, for
which FDA has granted a Fast Track Designation; non-alcoholic
steatohepatitis (NASH) is also being explored. In addition,
POSIMIR® (bupivacaine solution) for infiltration use, a
non-opioid analgesic utilizing the innovative SABER® platform
technology, is FDA-approved and has been exclusively licensed to
Innocoll Pharmaceuticals for development and commercialization in
the United States. For more
information about DURECT, please
visit www.durect.com and follow us on
Twitter https://twitter.com/DURECTCorp.
DURECT Forward-Looking Statement
The statements
in this press release regarding clinical development of
larsucosterol (DUR-928) for potential treatment of AH, the
potential to develop larsucosterol for NASH or other
indications, the expected commercial launch of POSIMIR
by Innocoll and potential future payments we may
receive from Innocoll are forward-looking statements
involving risks and uncertainties that can cause actual results to
differ materially from those in such forward-looking statements.
Potential risks and uncertainties include, but are not limited to,
the risks that the AHFIRM trial of
larsucosterol in AH takes longer to conduct than anticipated
due to COVID-19 or other factors, the risk that ongoing and future
clinical trials of larsucosterol do not confirm
the results from earlier clinical or pre-clinical trials, or do not
demonstrate the safety or efficacy or the life-saving potential
of larsucosterol in a statistically significant
manner, risks that Innocoll may not
commercialize POSIMIR successfully, if at all, and
risks related to our ability to obtain capital to fund operations
and expenses. Further information regarding these and other risks
is included in DURECT's annual report on Form 10-Q
filed on May 5, 2022 with the
Securities and Exchange Commission under the heading "Risk
Factors." The 10-K and other public filings are available on
our website www.durect.com under the "Investors"
tab.
NOTE: POSIMIR® is a trademark of Innocoll Pharmaceuticals,
Ltd. in the U.S. and a trademark of DURECT Corporation outside of
the U.S. SABER® is a trademark of DURECT Corporation. Other
referenced trademarks belong to their respective
owners. Larsucosterol (DUR-928) is an investigational drug
candidate under development and has not been approved for
commercialization by the U.S. Food and Drug
Administration or other health authorities for any
indication.
View original
content:https://www.prnewswire.com/news-releases/durect-corporation-to-present-at-the-hc-wainwright-global-investment-conference-301550478.html
SOURCE DURECT Corporation